Nabin Poudel, PhD
Awards
Postdoctoral Fellowship
Integrating Patient Preferences into Cost Effectiveness Analysis: A Case Study for Kidney Transplant Rejection Monitoring Technologies
The Healthy Years in Total (HYT) provide a different way to measure health benefits. The aim is to address discrimination against patients with disabilities. However, HYT doesn’t consider patients preference, which is crucial for accepting treatments. This study plans to use HYT and patients’ preference information to explore the value of different methods to monitor kidney transplants (KT) rejection. These methods include traditional markers, biomarkers, and biopsies. Two main goals are set: 1) Create a cost-effectiveness analysis (CEA) for KT monitoring with HYT, using a Markov model to find the Incremental Cost-Effectiveness Ratio (ICER). 2) Integrate data from a pilot discrete choice experiment (DCE) into CEA for a patient-focused value assessment. The goal is to systematically combine patient preferences information from DCE into CEA. This could help better resource allocation, enhance traditional value assessment, and understand patients’ value for treatments.
Challenge Award Paper
Evidence Inventory: A Patient-Centered Methodological Framework for CMS to Assess the Clinical Benefit of Drugs to Inform Maximum Fair Price Negotiation
Authors: Nabin Poudel, PhD; Salome Ricci, PharmD, MS; Julia F. Slejko, PhD
The PhRMA Foundation awarded this paper a $25,000 Challenge Award for exploring crucial challenges facing the Centers for Medicare & Medicaid Services (CMS) in implementing Medicare drug price negotiation.
The paper addresses the issue of patient engagement in the CMS process. When evaluating evidence on the benefits of a drug as compared to therapeutic alternatives, CMS should engage in patient-centered approaches. The Poudel paper states, “there is a need for a patient-centric, clear, transparent, and rigorous framework to harmonize various sources of evidence.” The authors propose a four-step process to implement a patient-centered evidence inventory to systematically evaluate treatment benefits, including re-evaluating evidence as new information become available. “The involvement of patients in the evidence evaluation process ensures that patients’ perspectives and needs are considered, resulting in more patient-centered decision-making,” the authors wrote.
Read the paper in the Journal of Managed Care & Specialty Pharmacy.
The PhRMA Foundation’s Postdoctoral Fellowship in Value Assessment and Health Outcomes Research provides me with an excellent opportunity to strive toward incorporating patients’ preferences into value assessment research.
